HomeInsightsStock Comparison

Beta Drugs Ltd vs Suven Pharmaceuticals Ltd Stock Comparison

Beta Drugs Ltd vs Suven Pharmaceuticals Ltd Stock Comparison

Last Updated on: May 24, 2025

Key Highlights

  • The Latest Trading Price of Beta Drugs Ltd is ₹ 1720 as of 23 May 15:30.
  • The P/E Ratio of Beta Drugs Ltd changed from 4.1 on March 2020 to 32.5 on March 2024 . This represents a CAGR of 51.29% over 5 yearsThe P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 years.
  • The Market Cap of Beta Drugs Ltd changed from ₹ 38.46 crore on March 2020 to ₹ 1186 crore on March 2024 . This represents a CAGR of 98.53% over 5 yearsThe Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 years.
  • The revenue of Beta Drugs Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Suven Pharmaceuticals Ltd for the Dec '24 is ₹ 322.86 crore as compare to the Sep '24 revenue of ₹ 271.84 crore. This represent the growth of 18.77%.
  • The ebitda of Beta Drugs Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Suven Pharmaceuticals Ltd for the Dec '24 is ₹ 133.41 crore as compare to the Sep '24 ebitda of ₹ 118.13 crore. This represent the growth of 12.93%.
  • The net profit of Beta Drugs Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 83.29 crore over 7 quarters. This represents a CAGR of -19.06% .
  • The Dividend Payout of Beta Drugs Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Beta Drugs Ltd

  • Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005.
  • Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017 Beta Drugs is a part of Adley Group.
  • Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India.
  • The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers.
  • The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

Beta Drugs Ltd News Hub

News

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 15 May 2025. Po...

Read more

10 May 2025 10:59

News

Beta Drugs announces board meeting date

Beta Drugs will hold a meeting of the Board of Directors of the Company on 27 March 2025. ...

Read more

20 Mar 2025 14:34

News

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 5 February 2025...

Read more

03 Feb 2025 10:49

News

Beta Drugs schedules EGM

Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be h...

Read more

28 Nov 2024 15:41

News

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 6 November 2024...

Read more

04 Nov 2024 14:01

News

Beta Drugs to conduct EGM

Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be h...

Read more

21 Oct 2024 13:59

Suven Pharmaceuticals Ltd News Hub

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

News

Suven Pharmaceuticals Ltd Surges 5.19%

Suven Pharmaceuticals Ltd gained 5.19% today to trade at Rs 1099.95. The BSE Healthcare in...

Read more

13 Feb 2025 09:30

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Beta Drugs Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Beta Drugs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Beta Drugs Ltd and Suven Pharmaceuticals Ltd

Which company has a larger market capitalization, Beta Drugs Ltd or Suven Pharmaceuticals Ltd?

Market cap of Beta Drugs Ltd is 1,737 Cr while Market cap of Suven Pharmaceuticals Ltd is 27,584 Cr

What are the key factors driving the stock performance of Beta Drugs Ltd and Suven Pharmaceuticals Ltd?

The stock performance of Beta Drugs Ltd and Suven Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Beta Drugs Ltd and Suven Pharmaceuticals Ltd?

As of May 24, 2025, the Beta Drugs Ltd stock price is INR ₹1720.75. On the other hand, Suven Pharmaceuticals Ltd stock price is INR ₹1083.6.

How do dividend payouts of Beta Drugs Ltd and Suven Pharmaceuticals Ltd compare?

To compare the dividend payouts of Beta Drugs Ltd and Suven Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions